Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
The Z<sub>HER2:V2</sub>-pemetrexed conjugate could inhibit tumor growth of HER2-positive lung adenocarcinoma and may have the potential to become a targeted drug for lung cancer.
|
30578135 |
2020 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Using patient-derived organoids and xenografts established from an HER2-A775_G776YVMA-inserted advanced lung adenocarcinoma patient sample, we investigated the antitumor activity of pyrotinib.
|
30596880 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in human epidermal growth factor receptor 2 (HER2; also known as ERBB2) are found in approximately 2% of lung adenocarcinomas.
|
31469421 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we sought to characterize tumor proteome and phosphoproteome changes by longitudinal, prospective collection of tumor tissue from an exceptional responder lung adenocarcinoma patient who survived with metastatic lung adenocarcinoma for over seven years while undergoing HER2-directed therapy in combination with chemotherapy.
|
30617155 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component.
|
30825613 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We collected information on 27 patients with stage IV or recurrent HER2-mutant lung adenocarcinomas treated with afatinib.
|
30685684 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Thus, the Z<sub>HER2:V2</sub>-pemetrexed conjugate may serve as a novel molecular agent with tremendous clinical breakthrough potential in the diagnosis and treatment of HER2-positive lung adenocarcinoma.
|
31758360 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Molecular analysis (EGFR, KRAS, BRAF, ALK, HER2) was performed in 44 metastases of lung adenocarcinomas.
|
29852147 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lung adenocarcinomas with HER2 gene mutation exhibit an aggressive behavior manifesting by higher incidence of local invasion, compared to KRAS and EGFR mutant controls, and a nodal metastatic spread compared to KRAS-mutant control.
|
29906786 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the efficacy of first line chemotherapy in patients with advanced HER2-mutant lung adenocarcinomas.
|
29587667 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HER2 and HER3 expression and activating EGFR mutations in surgically resected lung adenocarcinoma exhibiting ground glass nodules on chest computed tomography and re-classified to stage 0 and IA1 were examined by immunohistochemistry and peptide nucleic acid-locked nucleic acid PCR clamp method, respectively.
|
29473311 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The expression of C-Met and HER2 protein in lung adenocarcinoma is highly correlated, and whether it is synergistic in the targeted therapy of lung adenocarcinoma deserves further study.
|
29400000 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
|
30149884 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Results We treated 18 patients with advanced HER2-mutant lung adenocarcinomas.
|
29989854 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic HER2 mutations are present in 2-4% of lung adenocarcinomas, but the relevant clinical trials are unsatisfactory.
|
30527195 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we reported the first clinical evidence of efficacy generated by afatinib, the irreversible HER family inhibitor, targeting HER2 S310Y single site mutation in lung adenocarcinoma.
|
29561699 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report.
|
30295016 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We showed patients with ERBB2-mutated lung adenocarcinoma can respond to targeted therapies, and we identified potential resistance mechanisms upon progression to targeted therapies.
|
28167203 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HER2 mutations were detected in 3% of patients with lung adenocarcinoma in the LCMC.
|
28743157 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Gene rearrangements, including ALK, ROS1 and RET, and gene mutations, including epidermal growth factor receptor (EGFR), HER2, Kristen rat sarcoma viral oncogene homolog, BRAF, phosphoinositide‑3‑kinase, catalytic, α polypeptide and MET, have been identified in lung adenocarcinoma, which enable targeted therapy in lung adenocarcinoma, for example erlotinib, gefitinib and afatinib, which are EGFR inhibitors.
|
29039585 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the frequency and clinicopathological significance of HER2 dysregulation in patients with lung adenocarcinoma.
|
28146588 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HER2 mutations are found in about 2% of lung adenocarcinomas (ADCs).
|
28152008 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HER2 TMD mutations represent rare but distinct targetable driver mutations in lung adenocarcinoma.
|
27903463 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HER2 mutation was identified in 40 (4.5%) lung ADC patients.
|
28063177 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in EGFR, KRAS, erb-b2 receptor tyrosine kinase 2 gene (ERBB2), and BRAF; gene fusions involving anaplastic lymphoma receptor tyrosine kinase gene (ALK), ROS1, and ret proto-oncogene (RET); and Met Proto-Oncogene Tyrosine Kinase (MET) exon 14 skipping were the major drivers in LUAD in Asians, exhibiting mutually exclusive and differing prevalence from those reported in studies of LUAD in non-Asians.
|
27615396 |
2016 |